GALECTIN THERAPEUTICS INC — Director's Dealing 2014

Jan 14, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2014-01-10

Reporting Person: CZIRR JAMES C (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-01-10	Common Stock	S	42000	$16.0028	Disposed	9415422	Indirect
2014-01-13	Common Stock	S	58000	$14.0035	Disposed	9357422	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	844450	Direct
Common Stock	179232	Indirect

Footnotes

F1: The Issuer is aware of potential short-swing liability issues related to the transaction reported herein and a transaction reported by the Issuer's Executive Chairman that occurred on November 15, 2013. The issuer is taking steps to collect any short-swing profit created by such transactions.

F2: Reflects weighted average price. Range of prices were between $15.68 and $16.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F3: Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.

F4: Reflects weighted average price. Range of prices were between $13.65 and $14.23. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.